Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
메프로바메이트
메프로바메이트 · Diron · Mendel · Erina · Klort · Letyl · CaMHA · Oasil

식별자 및 물리적 특성
| CAS No. | 57-53-4 |
|---|---|
| 분자식 | C9H18N2O4 |
| 평균 분자량 | 218.25 g/mol |
| 단동위원소 질량 | 218.12665706 g/mol |
| SMILES | CCCC(C)(COC(N)=O)COC(N)=O |
| InChIKey | NPPQSCRMBWNHMW-UHFFFAOYSA-N |
| PubChem CID | 4064 |
| ChEMBL | CHEMBL979 |
| ChEBI | CHEBI:6761 |
| EC No. | 200-337-5 |
| DTXSID | DTXSID3023261 |
| 현지명 | 메프로바메이트 |
화학 및 물리적 성질
| XLogP | 0.7 |
|---|---|
| 극성 표면적 | 105 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 4 |
| 회전 가능 결합 수 | 8 |
| 무거운 원자 수 | 15 |
| 형식 전하 | 0 |
| 복잡도 | 212 |
| 물질 분류 | Pharmaceutical |
| 의약품 | DEA NFLIS-Drug Category -> Depressants and TranquilizersDEA Schedule IV Controlled Substance -> DepressantsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> HypnoticsPharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds |
| pH | Aqueous solutions are neutral |
| SpringerMaterials Properties | Fusion temperature |
| LogP(분배 계수) | log Kow = 0.701.12 |
| 냄새 | Characteristic odor |
| 맛 | Characteristic bitter taste |
| Color/Form | Crystals from hot waterWhite powder |
| 용해도 | less than 1 mg/mL at 68 °F (NTP, 1992)Very soluble in benzene, ethyl ether, ethanolEasily forms supersaturated solution with hot waterfreely soluble in most org solventsSolubility in water: 0.34% (w/w) at 20 °C0.79% at 37 °C (w/w)Slightly sol in ethersol in alcohol and acetone.DMF: 50 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 30 mg/mlEthanol: 25 mg/ml |
| Human Drugs | Breast FeedingLactationMilk, HumanAnti-Anxiety AgentsHypnotics and SedativesMuscle Relaxants, CentralFDA approved drugs -> Active ingredient |
| Animal Drugs | Pharmaceuticals -> Animal Drugs -> Approved in Taiwan |
| Decomposition | When heated to decomp it emits toxic fumes of /nitrogen oxides./ |
| 녹는점 | 97-100°C |
| 끓는 점 | 358.93°C (rough estimate) |
| 밀도 | 1.2004 (rough estimate) |
| 굴절률 | 1.4480 (estimate) |
| 인화점 | 11 °C |
| 저장 조건 | 2-8°C |
| pKa(산도 계수) | 13.09±0.50(Predicted) |
| 용해도 | 6.2g/L(25℃) |
| 헨리 상수 | 5.5×104 mol/(m3Pa) at 25℃, HSDB (2015) |
| 안정성 | 안정적인. 타기 쉬운. 강한 산화제와 호환되지 않습니다. |
| NIST | 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate(57-53-4) |
| EPA | Meprobamate (57-53-4) |
화학적 성질
white crystalline powder
안전 및 규제
| GHS 분류 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| 규제 정보 | Hazard Traits - Developmental ToxicityDEA schedule IV controlled substance1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate: Does not have an individual approval but may be used under an appropriate group standard |
| 기타 안전 정보 | IMAP assessments - 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate: Environment tier I assessment |
| 화재 위험 | Flash point data for this chemical are not availablehowever, it is probably combustible. (NTP, 1992) |
| 건강 유해성 | SYMPTOMS: Symptoms of exposure upon ingestion of this compound may include coma, blood pressure decrease, regional or general arteriolar constriction, dyspnea, cyanosis, respiratory depression, nausea, vomiting and allergic skin dermatitis. Other symptoms may include slight alterations of binocular vision and slight tendency to euphoria. Exposure to this compound may also cause drowsiness, diarrhea, paresthesia, weakness, headache, excitement, dizziness, ataxia, disturbances of vision, tachycardia, erythema multiform and, occasionally, skin rashes, angioneurotic edema, bronchospasm, anuria, agranulocytosis, eosinophilia, leucopenia and aplastic anemia. Other symptoms may include purpura, hypotension, cardiac arrhythmias and, occasionally, urticaria and thrombocytopenia. Exposure to this compound may result in acute intermittent porphyria, allergic or idiosyncratic reactions, slurred speech, vertigo, overstimulation, fast EEG activity, palpitations, arrhythmia, transient ECG changes, syncope, hypotensive crises, petechiae, ecchymoses, peripheral edema, adenopathy, fever, lethargy, stupor, shock, vasomotor and respiratory collapse, death, increased risk of congenital malformations and, rarely, hyperpyrexia, chills, oliguria, exfoliative dermatitis, anaphylaxis, stomatitis, proctitis, Stevens-Johnson syndrome and bullous dermatitis. Central nervous system depression may also occur. Other symptoms may include blood dyscrasias and hypothermia. Exposure to this compound also causes sleepiness, unsteadiness, mental confusion, slow and shallow respiration, flaccid muscles, hyperthermia, aspiration pneumonia, signs of lung consolidation, cerebral edema, laryngospasm, hangover emotional lability or depression, irritability, poor judgment, behavioral disturbances, vascular collapse, cardiac arrest and nonthrombocytopenic purpura. Other symptoms may include erythematous rash, angioedema, impaired stance and heart failure. In addition, areflexia, lack of response to sensory stimuli, excess oronasal secretions, relaxation of the pharyngeal wall muscular relaxation, pruritic eruptions, anaphylactoid reaction, fatal allergic collapse, fixed and unresponsive pupils, atelectasis and epileptiform seizures may occur. |
용도
용도
An anxiolytic. This is a controlled substance.
일반 설명
Meprobamate,2-methyl-2-propyltrimethylene dicarbamate, 2-methyl-2-propyl-1,3-propanediol dicarbamate (Equanil, Miltown), is officiallyindicated as an antianxiety agent. It is also a sedative–hypnotic agent. It has several overall pharmacological properties resembling those of benzodiazepines and barbiturates.The mechanism of action underlying anxiolytic effectsis unknown but may involve effects on conductivity inspecific brain areas.It does not appear to act through effectson GABAergic systems.The drug is effective againstabsence seizures and may worsen generalized tonic–clonicseizures.